Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese

NCT01679028 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: T89 Group A
DRUG: Placebo Group A
DRUG: Placebo Group B
DRUG: T89 Group B
DRUG: Placebo Group C
DRUG: T89 Group C

Sponsor

Tasly Pharmaceuticals, Inc.

Collaborators

[object Object]